Evidence map›Paper›PMID 34511651›Full record

ArticleActa histochemica et cytochemica2021

Forkhead Box I1 in Breast Carcinoma as a Potent Prognostic Factor.

Yoshiaki Onodera, Kiyoshi Takagi, Yoshimi Neoi, Ai Sato, Mio Yamaguchi, Yasuhiro Miki, Akiko Ebata, Minoru Miyashita, Hironobu Sasano, Takashi Suzuki

Open access · diamondAbstract read
In one paragraph

Article in Acta histochemica et cytochemica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yoshiaki OnoderaDepartment of Anatomic Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kiyoshi TakagiDepartment of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yoshimi NeoiDepartment of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Ai SatoDepartment of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Mio YamaguchiDepartment of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yasuhiro MikiDepartment of Anatomic Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Akiko EbataDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Minoru MiyashitaDepartment of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hironobu SasanoDepartment of Anatomic Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Takashi SuzukiDepartment of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Forkhead box (FOX) proteins are family of transcriptional factors and regulate cell growth and differentiation as well as embryogenesis and longevity. Previous studies have demonstrated that several FOX members regulate growth or metastasis of breast carcinoma, but clinical significance of total FOX members remains unclear. We first examined associations between expression of 40 FOX genes and TNM status of 19 breast carcinoma using microarray data. Subsequently, we immunolocalized FOXI1 in 140 breast carcinomas and evaluated its clinicopathological significance. In the microarray analysis, we newly identified that gene expression of FOXI1 was most pronouncedly linked to metastasis of the breast carcinoma among the FOX members examined. However, clinicopathological significance of FOXI1 has not been examined in the breast carcinoma. FOXI1 immunoreactivity was positive in 44 out of 140 (31%) of breast carcinomas, and it was significantly associated with stage, lymph node metastasis and distant metastasis. The FOXI1 status was significantly associated with worse prognosis of the breast cancer patients, and it turned out to be an independent prognostic factor for both distant disease-free survival and breast cancer-specific survival. These findings suggest that FOXI1 plays important roles in the metastasis of breast carcinoma and immunohistochemical FOXI1 status is a potent prognostic factor.

Indexed as

breast cancerForkhead box (FOX)immunohistochemistrymetastasisprognosis

Identifiers

PMID34511651
PMCPMC8424250
OpenAlexW3189830427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.